Outpatient parenteral antimicrobial therapy (OPAT) allows patients with clinically stable infections (e.g., skin and soft tissue infections, bone and joint infections, osteomyelitis, intra-…
Glaucoma refers to a group of chronic, progressive eye diseases caused primarily by elevated intraocular pressure (IOP), which left untreated can lead to damage of the optic nerve and eventual…
The availability of novel disease-modifying therapies (DMTs)—oral DMTs, Plegridy, and Lemtrada—has complicated clinical decision making and treatment choice in the management of multiple…
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease (MND), is a degenerative disorder of the nervous system characterized by progressive muscle…
The symptomology of Parkinson’s disease (PD) is heterogeneous; individual patients experience different combinations of primary motor symptoms, complications of therapy, and/or key nonmotor…
Osteoporosis is a common bone disease estimated to have affected 24.5 million U.S. patients in 2014, although owing to the asymptomatic nature of osteoporosis, the disease remains underdiagnosed. U…
Last Updated 2 October 2015 A new era in the market for multiple sclerosis (MS) disease-modifying therapies (DMTs) has dawned: Novartis/Mitsubishi Tanabe Pharma’s fingolimod (Gilenya/Imusera) and…
How Will Physician and Payer Attitudes and Decisions Shape this Market? The treatment of metastatic colorectal cancer (mCRC) is increasingly driven by patients’ RAS mutational status of their…
How Will Healthcare Reform and Payer-Led Cost-Containment Strategies Impact U.S. Prescribing? The market opportunity for hepatitis C virus (HCV) features a large prevalent population, a…
Juvenile idiopathic arthritis (JIA) is an autoimmune, rheumatologic disease characterized by joint inflammation, pain, and stiffness. JIA encompasses multiple forms of chronic arthritis in children…
A sudden, mechanical head injury that disrupts brain function is termed traumatic brain injury (TBI). Motor vehicle accidents, violence, and falls are the most common causes of TBI. Symptoms such…
For the estimated 700,000 people in the United States who suffer from Crohn’s disease (CD), there are multiple prescription therapies that are available for treating the associated symptoms. The…
How Does Cost versus Dosing Impact Prescriber Preferences and Payer Policy? The prevalence of age-related macular degeneration (AMD) is increasing with the aging population in China. Therapies…
Dyslipidemia is a risk factor for the development of cardiovascular disease and one of the most prevalent diseases in the United States. The efficacy of statins has led to their dominance in the…
Last Updated 28 September 2015 The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous commercial opportunity driven by considerable unmet need and looming societal burden. The…